ArticleGeneral psychiatry2025
Explainable and externally validated machine learning for neurocognitive diagnosis via ECGs.
Article in General psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Electrocardiogram (ECG) analysis has emerged as a promising tool for detecting physiological changes linked to non-cardiac disorders. Given the close connection between cardiovascular and neurocognitive health, ECG abnormalities may be present in individuals with co-occurring neurocognitive conditions. This highlights the potential of ECG as a biomarker to improve detection, therapy monitoring and risk stratification in patients with neurocognitive disorders, an area that remains underexplored. Aims: We aimed to demonstrate the feasibility of predicting neurocognitive disorders from ECG features across diverse patient populations. Methods: ECG features and demographic data were used to predict neurocognitive disorders, as defined by the International Classification of Diseases 10th revision, focusing on dementia, delirium and Parkinson's disease. Internal and external validations were performed using the Medical Information Mart for Intensive Care IV and ECG-View datasets. Predictive performance was assessed by the area under the receiver operating characteristic curve (AUROC) scores, and Shapley values were used to interpret feature contributions. Results: Significant predictive performance was observed for several neurocognitive disorders. The highest predictive performance was observed for F03: dementia, with an internal AUROC of 0.848 (95% confidence interval (CI) 0.848 to 0.848) and an external AUROC of 0.865 (95% CI 0.864 to 0.965), followed by G30: Alzheimer's disease, with an internal AUROC of 0.809 (95% CI 0.808 to 0.810) and an external AUROC of 0.863 (95% CI 0.863 to 0.864). Feature importance analysis revealed both established and novel ECG correlates. Conclusions: These findings suggest that ECG holds promise as a non-invasive, explainable biomarker for selected neurocognitive disorders. This study demonstrates robust performance across cohorts and lays the groundwork for future clinical applications, including early detection and personalised monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.